News | February 16, 2026
Agilent’s PD-L1 test gains FDA nod for ovarian cancer
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The move strengthens GBL’s clinical-stage presence in the United States
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Subscribe To Our Newsletter & Stay Updated
